Castle Biosciences has reported preliminary data from its ongoing study of an atopic dermatitis (AD) pipeline test for individuals with moderate-to-severe conditions.
The test aims to detect patients more likely to achieve a ‘super response’ to targeted therapies, marked by a 90% or greater decrease in disease severity as per the Eczema Area and Severity Index (EASI) score within three months.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With over 1,100 subjects enrolled across 39 clinical study sites, the company is developing and validating this study.
By detecting the immune pathways driving the disease, the test could lead to ‘effective’ treatment strategies, reducing the current ‘trial-and-error’ method. The company anticipates launching the test by the end of next year.
Castle Biosciences president and CEO Derek Maetzold said: “It is estimated that there are more than six million patients diagnosed with moderate-to-severe AD in the US seeking treatment annually, and approximately 760,000 of these patients seek systemic treatment.
“Today, once a clinician and patient determine that systemic therapy is needed to control the patient’s AD, a ‘trial-and-error’ treatment cycle begins. This ‘trial-and-error’ approach results in approximately 25% of patients discontinuing their initial systemic therapy. Separately, approximately 50% of patients who stay on their initial therapy have indicators of persistent disease burden.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe test analyses gene expression offering a precision medicine tool to improve patient outcomes and reduce healthcare resource utilisation.
Castle is currently planning the launch strategy for its test, which includes determining the reimbursement pathway.
